TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
ImmunoIVD AB
Closing information (x1000 NOK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
60,094
|
49,876
|
40,079 |
| Financial expenses |
1,566
|
1,710
|
1,495 |
| Earnings before taxes |
13,821
|
4,463
|
5,259 |
| EBITDA |
17,171
|
8,129
|
9,058 |
| Total assets |
43,870
|
33,322
|
29,550 |
| Current assets |
37,675
|
27,012
|
23,721 |
| Current liabilities |
25,311
|
25,147
|
22,824 |
| Equity capital |
18,559
|
8,174
|
6,726 |
| - share capital |
103
|
101
|
95 |
| Employees (average) |
27
|
25
|
23 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
42.3%
|
24.5%
|
22.8% |
| Turnover per employee |
2,226
|
1,995
|
1,743 |
| Profit as a percentage of turnover |
23.0%
|
8.9%
|
13.1% |
| Return on assets (ROA) |
35.1%
|
18.5%
|
22.9% |
| Current ratio |
148.8%
|
107.4%
|
103.9% |
| Return on equity (ROE) |
74.5%
|
54.6%
|
78.2% |
| Change turnover |
9,319
|
6,952
|
6,681 |
| Change turnover % |
18%
|
16%
|
20% |
| Chg. No. of employees |
2
|
2
|
-3 |
| Chg. No. of employees % |
8%
|
9%
|
-12% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.